Uppsala BIO builds new ways to make life science flourish in Uppsala, in close collaboration with industry, academy, healthcare and society.
Learn more about our program.
Uppsala BIO builds new ways to make life science flourish in Uppsala, in close collaboration with industry, academy, healthcare and society.
Learn more about our program.
Supporting the Scientists: Working as a research technician in a Core Service...Chris Willmott
Shairbanu Ashra graduated from the University of Leicester in 2004 with a degree in Medical Biochemistry, and completed an MSc in Pathology and Toxicology the following year. Since 2005 she has worked in the Proteomics division of the Protein and Nucleic Acid Chemistry Laboratory (PNACL), a support service for scientists at the University.
Slides from a Careers After Biological Sciences talk at the University of Leicester. The speaker was Dr James Lonnen and the subject was technology transfer, specifically the use of microbiological expertise in the testing of, for example, contact lense solutions.
(c) James Lonnen, 2009
Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...Chris Willmott
These are the slides from a presentation "Biopharmaceutical Process Development: Good Manufacturing Practices or Breaking Bad?" given by Andrew Warr as part of the 2015 Careers After Biological Sciences programme at the University of Leicester UK
The Medwin Publishers Providing Various Open Access Journals.
Open access makes published work immediately and permanently available online for everyone globally. MedWin is delighted to offer a variety of open access options for all the authors to publish their work with us.
Slides from a presentation given by Suzanna Hawkey (Public Health England) as part of the 2016 Careers After Biological Sciences season at the University of Leicester, UK.
As well as describing her role, Suzanna gave insights into the principles of handling highly contagious organisms, and generic tips for anyone considering applying for a similar job.
Dr Peter Meacock gave a talk in the 2007 Careers After Biological Science seminar series on "Doing a PhD". These are his slides (slightly revised in June 2009).
Hans Lund: Background and Introduction to the COST Action EVBRESCaroline Blaine
Feb 2019: Prof Hans Lund's presentation on the background to what EVBRES is, why it is important and its main aims. See www.evbres.eu for more information.
The focus of the Biotech Cluster Rhine-Neckar (BioRN) is on the development of innovative drugs, diagnostics and platform technologies in the field of cell-based and molecular medicine. With this brochure we would like to give you an impression of the highly concentrated knowledge and expertise in medical and biotechnical
research – at our cluster in general and at the Heidelberg Campus Neuenheimer Feld in particular.
While composing this information we, once again, became aware of the impressive number of joint projects and the tight relations and affiliations in our biotech cluster. It is this network that makes highly effective medical research possible, not only for the research institutes but also for the BioRN companies involved – a good reason for companies from outside the BioRN Cluster to join our network and to participate in one of the most innovative
regions in Germany.
The Innovation Tour mainly guides you through the Heidelberg University Campus Neuenheimer Feld and gives you an insight into its institutes and facilities. The tour starts in the north of the campus, at Heidelberg Technology Park (see page 4).
Please do not hesitate to contact us (info@BioRN.org) if you have questions on the Biotech Cluster Rhine-Neckar.
Klara Brunnhuber: Research Waste when Justifying New ResearchCaroline Blaine
Klara Brunnhuber, Vice Chair of EVBRES COST Action on how researchers currently justify a new study and why this lack of a systematic and transparent approach leads to research waste.
Presentation of a descriptive anaysis of the DCI from Thomson Reuters by Daniel Torres-Salinas, Evaristo Jiménez-Contreras and Nicolás Robinson-García at the STI Conference held in Leiden (The Netherlands) 3-5 september 2014 sti2014.cwts.nl
Supporting the Scientists: Working as a research technician in a Core Service...Chris Willmott
Shairbanu Ashra graduated from the University of Leicester in 2004 with a degree in Medical Biochemistry, and completed an MSc in Pathology and Toxicology the following year. Since 2005 she has worked in the Proteomics division of the Protein and Nucleic Acid Chemistry Laboratory (PNACL), a support service for scientists at the University.
Slides from a Careers After Biological Sciences talk at the University of Leicester. The speaker was Dr James Lonnen and the subject was technology transfer, specifically the use of microbiological expertise in the testing of, for example, contact lense solutions.
(c) James Lonnen, 2009
Biopharmaceutical Process Development: Good Manufacturing Practices or Breaki...Chris Willmott
These are the slides from a presentation "Biopharmaceutical Process Development: Good Manufacturing Practices or Breaking Bad?" given by Andrew Warr as part of the 2015 Careers After Biological Sciences programme at the University of Leicester UK
The Medwin Publishers Providing Various Open Access Journals.
Open access makes published work immediately and permanently available online for everyone globally. MedWin is delighted to offer a variety of open access options for all the authors to publish their work with us.
Slides from a presentation given by Suzanna Hawkey (Public Health England) as part of the 2016 Careers After Biological Sciences season at the University of Leicester, UK.
As well as describing her role, Suzanna gave insights into the principles of handling highly contagious organisms, and generic tips for anyone considering applying for a similar job.
Dr Peter Meacock gave a talk in the 2007 Careers After Biological Science seminar series on "Doing a PhD". These are his slides (slightly revised in June 2009).
Hans Lund: Background and Introduction to the COST Action EVBRESCaroline Blaine
Feb 2019: Prof Hans Lund's presentation on the background to what EVBRES is, why it is important and its main aims. See www.evbres.eu for more information.
The focus of the Biotech Cluster Rhine-Neckar (BioRN) is on the development of innovative drugs, diagnostics and platform technologies in the field of cell-based and molecular medicine. With this brochure we would like to give you an impression of the highly concentrated knowledge and expertise in medical and biotechnical
research – at our cluster in general and at the Heidelberg Campus Neuenheimer Feld in particular.
While composing this information we, once again, became aware of the impressive number of joint projects and the tight relations and affiliations in our biotech cluster. It is this network that makes highly effective medical research possible, not only for the research institutes but also for the BioRN companies involved – a good reason for companies from outside the BioRN Cluster to join our network and to participate in one of the most innovative
regions in Germany.
The Innovation Tour mainly guides you through the Heidelberg University Campus Neuenheimer Feld and gives you an insight into its institutes and facilities. The tour starts in the north of the campus, at Heidelberg Technology Park (see page 4).
Please do not hesitate to contact us (info@BioRN.org) if you have questions on the Biotech Cluster Rhine-Neckar.
Klara Brunnhuber: Research Waste when Justifying New ResearchCaroline Blaine
Klara Brunnhuber, Vice Chair of EVBRES COST Action on how researchers currently justify a new study and why this lack of a systematic and transparent approach leads to research waste.
Presentation of a descriptive anaysis of the DCI from Thomson Reuters by Daniel Torres-Salinas, Evaristo Jiménez-Contreras and Nicolás Robinson-García at the STI Conference held in Leiden (The Netherlands) 3-5 september 2014 sti2014.cwts.nl
2016-11-28 Mentlife seminar: Pharmaceutical Drug Development; An Overall Pers...MentLife
This seminar provided an understanding of modern pharmaceutical drug development – the different phases of drug development and insight into different jobs.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Improving Regional Competitiveness: The Vinnväxt Program and Uppsala BIO – th...Robin Teigland
This presentation describes the Vinnväxt Program in Sweden, which is designed to promote regional competitiveness. It presents a case study of one biotech cluster initiative, Uppsala BIO - the Life Science Initiative.
Find out about collaboration and partnership opportunities with the Wellcome Sanger Institute that aims to create exceptional healthcare opportunities for everyone from extraordinary science.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
New Explore Careers and College Majors 2024.pdfDr. Mary Askew
Explore Careers and College Majors is a new online, interactive, self-guided career, major and college planning system.
The career system works on all devices!
For more Information, go to https://bit.ly/3SW5w8W
Want to move your career forward? Looking to build your leadership skills while helping others learn, grow, and improve their skills? Seeking someone who can guide you in achieving these goals?
You can accomplish this through a mentoring partnership. Learn more about the PMISSC Mentoring Program, where you’ll discover the incredible benefits of becoming a mentor or mentee. This program is designed to foster professional growth, enhance skills, and build a strong network within the project management community. Whether you're looking to share your expertise or seeking guidance to advance your career, the PMI Mentoring Program offers valuable opportunities for personal and professional development.
Watch this to learn:
* Overview of the PMISSC Mentoring Program: Mission, vision, and objectives.
* Benefits for Volunteer Mentors: Professional development, networking, personal satisfaction, and recognition.
* Advantages for Mentees: Career advancement, skill development, networking, and confidence building.
* Program Structure and Expectations: Mentor-mentee matching process, program phases, and time commitment.
* Success Stories and Testimonials: Inspiring examples from past participants.
* How to Get Involved: Steps to participate and resources available for support throughout the program.
Learn how you can make a difference in the project management community and take the next step in your professional journey.
About Hector Del Castillo
Hector is VP of Professional Development at the PMI Silver Spring Chapter, and CEO of Bold PM. He's a mid-market growth product executive and changemaker. He works with mid-market product-driven software executives to solve their biggest growth problems. He scales product growth, optimizes ops and builds loyal customers. He has reduced customer churn 33%, and boosted sales 47% for clients. He makes a significant impact by building and launching world-changing AI-powered products. If you're looking for an engaging and inspiring speaker to spark creativity and innovation within your organization, set up an appointment to discuss your specific needs and identify a suitable topic to inspire your audience at your next corporate conference, symposium, executive summit, or planning retreat.
About PMI Silver Spring Chapter
We are a branch of the Project Management Institute. We offer a platform for project management professionals in Silver Spring, MD, and the DC/Baltimore metro area. Monthly meetings facilitate networking, knowledge sharing, and professional development. For event details, visit pmissc.org.
NIDM (National Institute Of Digital Marketing) Bangalore Is One Of The Leading & best Digital Marketing Institute In Bangalore, India And We Have Brand Value For The Quality Of Education Which We Provide.
www.nidmindia.com
The Impact of Artificial Intelligence on Modern Society.pdfssuser3e63fc
Just a game Assignment 3
1. What has made Louis Vuitton's business model successful in the Japanese luxury market?
2. What are the opportunities and challenges for Louis Vuitton in Japan?
3. What are the specifics of the Japanese fashion luxury market?
4. How did Louis Vuitton enter into the Japanese market originally? What were the other entry strategies it adopted later to strengthen its presence?
5. Will Louis Vuitton have any new challenges arise due to the global financial crisis? How does it overcome the new challenges?Assignment 3
1. What has made Louis Vuitton's business model successful in the Japanese luxury market?
2. What are the opportunities and challenges for Louis Vuitton in Japan?
3. What are the specifics of the Japanese fashion luxury market?
4. How did Louis Vuitton enter into the Japanese market originally? What were the other entry strategies it adopted later to strengthen its presence?
5. Will Louis Vuitton have any new challenges arise due to the global financial crisis? How does it overcome the new challenges?Assignment 3
1. What has made Louis Vuitton's business model successful in the Japanese luxury market?
2. What are the opportunities and challenges for Louis Vuitton in Japan?
3. What are the specifics of the Japanese fashion luxury market?
4. How did Louis Vuitton enter into the Japanese market originally? What were the other entry strategies it adopted later to strengthen its presence?
5. Will Louis Vuitton have any new challenges arise due to the global financial crisis? How does it overcome the new challenges?
Exploring Career Paths in Cybersecurity for Technical CommunicatorsBen Woelk, CISSP, CPTC
Brief overview of career options in cybersecurity for technical communicators. Includes discussion of my career path, certification options, NICE and NIST resources.
Exploring Career Paths in Cybersecurity for Technical Communicators
AstraZeneca, Lund, May 7 2014
1. Lund
May 7, 2014
Shalini Andersson, CVMD
Mikael Varga, RIA
Per-Erik Strömstedt, Discovery Sciences
Magnus Klarqvist, RIA
AstraZeneca R&D Mölndal
2. Our commitment to making a meaningful difference in
healthcare is founded on our innovative science. The
pursuit of scientific excellence that addresses unmet
patient need guides everything we do.
Pascal Soriot
CEO
Mission: To push the boundaries of science to
deliver life-changing medicines
3. Om AstraZeneca
With three strategic priorities
Achieve
Scientific
Leadership
Be a great
place to work
Return
to growth
Our strategy is focused on innovation
4. Increase proximity to bioscience clusters
and co-locate around three strategic sites
4
Proximity to NIH,
Johns Hopkins
New site in Cambridge with close proximity
to University of Cambridge and world class
UK bioscience community
Connections to Karolinska
Institute & Medicon Valley
Gaithersburg MölndalCambridge
Leverage historical strength
Respiratory and CV/Met
Co-locate around
biologics/specialty care
Co-locate R&D in world-class
science cluster
5. Our research and development
To deliver the next generation
Biologics
Small
Molecules
Immuno -
therapies
Protein
engineering
Neuroscience
Infection
& Vaccines
CV-
Metabolism
Respiratory,
Inflammation
& Autoimmunity
Oncology
Core Therapy Areas Opportunity-focused
6. • Two iMeds - RIA and CVMD
• Safety and Discovery Sciences
• A large Development organisation
• Several centers of excellence, eg inhalation technologies and transgenics
• Proximity to academic centers and Europes largest hospital
AstraZeneca R&D Mölndal
8. 2,300 dedicated colleagues in Mölndal...
901 in Research – 2 iMeds
1,004 in Development - GMD
60 % women
40 % men
1,570 have an academic degree
570 have a PhD
>30 professorers
>30 post-docs
…including >250 scientists from 30 countries
who bring new insights, expertise and energy!
10. COPD
10
AZ has a strong and continuing presence in front line COPD care
based on bronchodilator/anti-inflammatory therapy
What’s next?
Hallmarks of COPD
COPD is mixed disease with both airway
obstructions and loss of functional lung
Breathlessness in COPD is
more than airflow obstruction
11. Our current focus in CVMD
• Cardiovascular and Metabolic diseases (CVMD)
Diabetic Nephropathy
Cardiac Regeneration
Islet Health and Metabolism
13. Cardiac Regeneration
Goal
To identify and develop small or large molecules that enhance endogenous
regenerative capacity of the heart for the treatment of post-MI cardiac dysfunction
and heart failure.
Vision
To launch a new therapy which will offer an entirely new treatment paradigm for
patients who are dying of heart failure today.
Induction of proliferation of
existing cardiomyocytes
Direct reprogramming of cardiac
fibroblasts into cardiomyocytes
or cardiac progenitors
Activation of resident cardiac
progenitor cells in the heart:
Epicardial progenitor cells
(EPDC) or cardiac stem cells
(CSC)
14. Discovery Sciences
14 Per-Erik Strömstedt | May 7, 2014 | Discovery Sciences
• Compound
management
• Biobanks
(clinical samples)
• Hit generation
• SAR screening
• Ion channel centre
of excellence
• Crystallography; first
structures, iterative structures
• NMR and other biophysical
techniques
• Fragment Chemistry
• Chemical Biology
• Computational biology
• Cheminformatics
• Predictive Chemistry
• Compound collection
enhancement
• Proteins
• Cells
• Transgenics
• Antibodies
DS
• Project support
• Statistical qualification
Discovery Sciences (DS) provides centralised, state-of-the art support for hit finding,
lead optimization and target validation for all therapeutic research areas with AZ.
• Assay development
• High content biology assays
16. We are driving
science through
collaborations…
…more than 90
partnerships in the
last three years
17. To deliver the next
generation of medicines
we must continue to find
ways to combine our
science with the best
science that’s happening
elsewhere
Challenging ourselves to
find new ways to break
through the barriers and
work more openly with
scientists in other
organisations who share
our passion for patients
and who can bring
different perspectives to
innovative research
20. Opportunities at AZ Mölndal
21 Author | 00 Month Year Set area descriptor | Sub level 1
60 Summer workers 2013
22 Master’s thesis students
6 Graduate students
33 Post-Docs
With the ambition to increase …
21. AstraZeneca Post-Doc Programme
Investing in innovative science
The next generation of scientific minds
AstraZeneca Post-Doc Programme gives post-doctoral scientists the chance
to undertake high-quality, innovative research in a cross-discipline scientific
environment within the pharmaceutical industry.
AstraZeneca post-doctoral scientists:
• Conduct independent, cutting-edge research in state-of-the-art facilities
• Collaborate with AstraZeneca scientists in discovery and drug
development teams
• Work alongside a world-leading academic advisor
• Publish their work in high-quality scientific journals and communicate research
findings at international scientific conferences.
Each scientist receives a tailored training and development programme, aligned with the established
AstraZeneca approach to personal development. This includes core training on drug discovery and
development, as well as on key skills, such as presentation delivery and publication writing.
22. AstraZeneca Internal
Post-doc Program
Post-doc proposal selection based on
• Scientific Novelty
• Feasability (Scientific, Technical and 2 yr time frame)
• Availability of academic collaborator
For more information on the opportunities of the programme,
visit:
http://www.astrazeneca.com/Research/capabilities/AstraZeneca-
expandspostdoc-program
For the latest vacancies, visit:
http://www.astrazenecacareers.com/students-all/postdoc-
program2/
25. Topushtheboundariesofsciencetodeliverlife-changingmedicines
>20 Clinical ready
compounds
>40 Mechanistic
tool compounds
up to $100K grants
Potential to partner
your molecules
Prizes for solutions
to R&D challenges
Partnerships
New clinically validated
projects
New lead optimization projects
New targets/hit ID projects
Access to novel molecules
Novel solutions
Clinical Compound
Bank
Pharmacology
Toolbox
Target Innovation
New Molecule
Profiling
R&D Challenges
Suggestion Box
Ideas for future
partnerships
Academics
Why is it Attractive?
AZ
GenerationofNoveldataforpublicationsandadvancemedicalscience
26. A global business
50,000 employees.
Research across 3 continents.
$4.2 billion invested in R&D in 2013.
Manufacturing in 17 countries.
Sales in 100 countries.
$25.7 billion sales in 2013.
27. AstraZeneca Mölndal
2 150
900
1 100
>250
employees
in Innovative Medicines
in Global Medicines Development
colleagues from 30 countries
1 614 with academic degree
574 PhDs
3
